Skip to main content
    N

    Nu Skin Enterprises Inc (NUS)

    Official site

    CONSUMER DEFENSIVE • HOUSEHOLD & PERSONAL PRODUCTS • NYSE

    $3.94
    -0.09 (-2.11%)

    Market Cap: $196.17M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Nu Skin Enterprises Inc (NUS) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Nu Skin Enterprises (NUS) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Nu Skin Enterprises reported EPS of $0.10, below the $0.21 estimate. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    67%(26/39)
    Avg Surprise
    +11.58%

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.27
    Range$0.26 - $0.28
    2 analysts
    Revenue Consensus
    $350.98M
    Range$340.55M - $364.88M
    2 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.16
    Range$0.16 - $0.16
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.23-30.4%
    60d ago$0.19-15.8%
    30d ago$0.19-15.8%
    7d ago$0.19-15.8%
    Current$0.16
    Revenue Consensus
    $328.70M
    Range$328.70M - $328.70M
    1 analysts

    Next Report

    NUS has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 6.9% below the $0.29 reported for the quarter ended Dec 31, 2025.

    NUS Earnings Call

    The latest NUS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, NUS beat 26, missed 9 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $311.01M, down 14.6% from $364.21M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.10$0.21$0.21 - $0.21-52.38%Miss-70.6%10 up, 1 downNov 5, 2026$311.01M
    Jun 30, 2026$0.20$0.20$0.20 - $0.200.00%In line-53.5%11 up, 0 downAug 9, 2026$320.11M
    Mar 31, 2026$0.14$0.15$0.15 - $0.15-6.67%Miss-93.4%10 up, 1 downMay 7, 2026$320.61M
    Dec 31, 2025$0.29$0.30$0.30 - $0.30-3.33%Miss-23.7%10 up, 1 downFeb 12, 2026$370.32M
    Sep 30, 2025$0.34$0.30$0.30 - $0.30+13.33%Beat+100.0%10 up, 1 downNov 6, 2025$364.21M
    Jun 30, 2025$0.43$0.25N/A+72.00%Beat+104.8%10 up, 1 downAug 7, 2025$386.14M
    Mar 31, 2025$2.14$0.15N/AN/AN/A+2273.7%10 up, 1 downMay 8, 2025$364.49M
    Dec 31, 2024$0.38$0.22$0.20 - $0.23+72.73%Beat+2.7%31 up, 1 downFeb 13, 2025$445.55M
    Sep 30, 2024$0.17$0.20$0.19 - $0.21-15.00%Miss-69.6%30 up, 0 downNov 7, 2024$430.14M
    Jun 30, 2024$0.21$0.17$0.15 - $0.20+23.53%Beat-61.1%30 up, 0 downAug 8, 2024$439.08M
    Mar 31, 2024$0.09$0.05$0.05 - $0.05+80.00%Beat-75.7%30 up, 0 downMay 8, 2024$417.31M
    Dec 31, 2023$0.37$0.28$0.24 - $0.33+32.14%Beat-58.4%40 up, 0 downFeb 14, 2024$488.64M
    Sep 30, 2023$0.56$0.62$0.57 - $0.69-9.68%Miss+19.1%40 up, 1 downNov 1, 2023$498.77M
    Jun 30, 2023$0.54$0.53$0.49 - $0.58+1.89%Beat-29.9%40 up, 0 downAug 1, 2023$500.26M
    Mar 31, 2023$0.37$0.33$0.29 - $0.35+12.12%Beat-51.3%40 up, 0 downMay 3, 2023$481.46M
    Dec 31, 2022$0.89$0.54$0.50 - $0.59+64.81%Beat+1.1%41 up, 0 downFeb 15, 2023$522.34M
    Sep 30, 2022$0.47$0.78$0.76 - $0.80-39.74%Miss-51.5%40 up, 0 downNov 2, 2022$537.80M
    Jun 30, 2022$0.77$0.75$0.65 - $0.85+2.67%Beat-33.0%51 up, 1 downAug 4, 2022$560.62M
    Mar 31, 2022$0.76$0.72$0.70 - $0.75+5.56%Beat-16.5%50 up, 0 downMay 4, 2022$604.90M
    Dec 31, 2021$0.88$0.95$0.92 - $1.00-7.37%Miss-37.1%5N/AFeb 16, 2022$673.44M
    Sep 30, 2021$0.97$0.86N/A+12.79%Beat-10.2%5N/ANov 3, 2021$641.15M
    Jun 30, 2021$1.15$1.06$1.00 - $1.07+8.49%Beat+42.0%6N/AAug 4, 2021$704.05M
    Mar 31, 2021$0.91$0.72$0.69 - $0.76+26.39%Beat+152.8%6N/AMay 5, 2021$677.03M
    Dec 31, 2020$1.40$1.18$1.15 - $1.24+18.64%Beat+94.4%7N/AFeb 10, 2021$748.19M
    Sep 30, 2020$1.08$0.96$0.83 - $1.05+12.50%Beat+36.7%7N/ANov 4, 2020$703.35M
    Jun 30, 2020$0.81$0.65$0.47 - $0.74+24.62%Beat-2.4%7N/AAug 5, 2020$612.37M
    Mar 31, 2020$0.36$0.25$0.18 - $0.33+44.00%Beat-53.2%7N/AMay 6, 2020$518.03M
    Dec 31, 2019$0.72$0.74N/A-2.70%Miss-31.4%7N/AFeb 12, 2020$583.36M
    Sep 30, 2019$0.79$0.76$0.74 - $0.79+3.95%Beat-24.8%7N/ANov 5, 2019$589.93M
    Jun 30, 2019$0.83$0.83$0.82 - $0.830.00%In line-23.1%8N/AAug 6, 2019$623.50M
    Mar 31, 2019$0.77$0.72$0.65 - $0.75+6.94%Beat-2.5%8N/AApr 30, 2019$623.62M
    Dec 31, 2018$1.05$1.05$1.01 - $1.100.00%In line-12.5%8N/AFeb 13, 2019$683.29M
    Sep 30, 2018$1.05$0.98N/A+7.14%Beat+38.2%N/AN/ANov 7, 2018$675.31M
    Jun 30, 2018$1.08$0.93$0.85 - $0.96+16.13%Beat+40.3%8N/AAug 2, 2018$704.19M
    Mar 31, 2018$0.79$0.70$0.59 - $0.81+12.86%Beat+54.9%6N/AApr 26, 2018$616.22M
    Dec 31, 2017$1.20$1.19$1.10 - $1.22+0.84%Beat+51.9%7N/AFeb 15, 2018$666.20M
    Sep 30, 2017$0.76$0.76$0.75 - $0.780.00%In line-14.6%6N/ANov 1, 2017$563.70M
    Jun 30, 2017$0.77$0.69$0.66 - $0.72+11.59%Beat-2.5%7N/AAug 2, 2017$550.10M
    Mar 31, 2017$0.51$0.50N/A+2.00%Beat+21.4%N/AN/AMay 3, 2017$499.10M
    Dec 31, 2016$0.79$0.80N/A-1.25%Miss+27.4%N/AN/AFeb 16, 2017$531.33M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $3.20, up 276.0% from the year before. It was $2.89 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$3.20+276.0%
    Dec 31, 2024$0.85-53.8%
    Dec 31, 2023$1.84-36.3%
    Dec 31, 2022$2.89-26.1%
    Dec 31, 2021$3.91+7.1%
    Dec 31, 2020$3.65+17.4%
    Dec 31, 2019$3.11-21.7%
    Dec 31, 2018$3.97+22.5%
    Dec 31, 2017$3.24+12.1%
    Dec 31, 2016$2.89N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,000 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,0105
    2026Q2Jun 30, 20263,6695
    2026Q1Mar 31, 20264,2655
    2025Q4Dec 31, 20254,5865
    2025Q3Sep 30, 20254,0155
    2025Q2Jun 30, 20253,6225
    2025Q1Mar 31, 20252,8424
    2024Q4Dec 31, 20244,0026

    2026Q3 Earnings Call

    Opening remarks

    B.G. Hunt VP of Investor Relations Thanks, Janelle, and good afternoon, everyone. I am joined by Ryan Napierski, President and CEO, and by our interim CFO, Chelsea Lantz. Today, we will be sharing Nu Skin's Q3 2026 results and providing guidance for the remainder of the year. Before I turn the time over to Ryan, let me point out that on today's call, comments will be made that include forward-looking statements. These statements involve important risks and uncertainties, and actual results may differ materially from those discussed or anticipated. Please refer to today's earnings release and our SEC filings for a complete discussion of these risks. Also, during the call, certain financial numbers may be discussed that differ from comparable numbers obtained in our financial statements. We believe these non-GAAP numbers assist in comparing period-to-period results in a more consistent manner. Please refer to our investor website, ir.nuskin.com, for any required reconciliation of these non-GAAP numbers. With that, I would now like to turn the call over to Ryan.

    Ryan Napierski President and CEO Thanks, B.G. Good afternoon, everyone, and thanks for joining for our third quarter call. We delivered revenue of $311 million and adjusted EPS of $0.10, both within our guidance range. Our Rhyz manufacturing platform had an exceptional quarter, posting strong year-over-year revenue growth. While our results reflect ongoing pressures in the core business, we remain focused on our strategic priorities that we have outlined over the last year. Our Chief Operating Officer, Chayce Clark, has been leading the team to simplify, focus, and execute upon each of them. These priorities are, number one, advancing our integrated anti-aging platform. Number two, strengthening our channel through improved sales force activation and development. Three, preparing for a formal launch of India early next year. And four, improving our operating model to support greater profitability over time. Let me briefly update you on each of these priorities. First, we continue to make progress in advancing our integrated anti-aging platform, with Prysm iO playing an increasingly important role in our approach to personalized wellness. Prysm is designed to help consumers better understand their nutritional health status and engage more consistently with our wellness product solutions, creating a differentiated experience that connects technology, products, and ongoing customer relationships. Since launching Prysm through the end of Q3, we have now placed approximately 41,000 devices globally and completed 4.5 million scans. During the quarter, we rolled out version 2.0 of the app, which delivers a meaningfully improved user experience powered by our new intelligence AI integration. Since the app update, we have more than doubled our scan-to-purchase conversion rate to 10%, which tells us that consumers are taking action when we get them more engaged with the platform.

    Frequently Asked Questions About NUS

    When is Nu Skin Enterprises's next earnings date?

    Nu Skin Enterprises's next earnings report is expected for Feb 10, 2027.

    Did NUS beat earnings estimates last quarter?

    No. Nu Skin Enterprises reported EPS of $0.10 for the quarter ended Sep 30, 2026, below the $0.21 estimate by 52.38%.

    What EPS do analysts expect from NUS next quarter?

    The consensus EPS estimate for Nu Skin Enterprises for the quarter ending Dec 31, 2026 is $0.27 from 2 analysts, with estimates from $0.26 to $0.28.

    How often does NUS beat earnings estimates?

    Nu Skin Enterprises beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of +10.08%.